Ovid Therapeutics Q4 2023 Earnings Report

Ovid Therapeutics EPS Results

• Actual EPS: -$0.22
• Consensus EPS: -$0.17
• Beat/Miss: Missed by -$0.05
• One Year Ago EPS: N/A

Ovid Therapeutics Revenue Results

• Actual Revenue: $0.14 million
• Expected Revenue: $0.10 million
• Beat/Miss: Beat by +$40.00 thousand
• YoY Revenue Growth: N/A

Ovid Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 3/8/2024
• Time: N/A
• Conference Call Date: Friday, March 8, 2024
• Conference Call Time: 7:00AM ET

Ovid Therapeutics (NASDAQ:OVID) is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome. OV101 has demonstrated proof-of-concept activity in early clinical studies, and ongoing trials aim to further characterize its safety and efficacy profiles. In parallel, Ovid is advancing OV935, a small-molecule inhibitor targeting specific kinase pathways implicated in CDKL5 deficiency disorder, a severe form of early-onset epilepsy.

To support its global development strategy, Ovid has established strategic collaborations with industry partners. A notable agreement grants regional rights for OV935 to a leading pharmaceutical company for select Asian markets. The company maintains additional research partnerships to broaden its preclinical pipeline and leverage external expertise in rare disease biology and regulatory science.

Ovid Therapeutics completed its initial public offering on the Nasdaq market in 2018 and continues to engage with regulatory authorities to advance its clinical programs toward potential approval. The organization is led by a management team with deep experience in neuroscience drug discovery and development, supported by a board of directors comprised of seasoned professionals in biopharma innovation and commercialization.